FDA warns of rare vision-loss side effect from GLP-1 drugs
The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with GLP-1 drugs like Ozempic, Wegovy and other brands.
Watch CBS News
The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with GLP-1 drugs like Ozempic, Wegovy and other brands.
Growing usage of GLP-1 drugs for weight loss is reshaping how consumers shop for food and clothes, according to consulting firm EY-Parthenon.
Researchers will explore whether weight-loss drugs can deter risky or impulsive financial decisions. "It might be very good financially for the average person," one neuroscientist said.
About 40 million Americans are on GLP-1 medications like Ozempic, Wegovy, Zepbound and Mounjaro.
Going on GLP-1 drugs significantly boosted unemployed women's chances of finding a job, according to a Harvard economist.
For the first time, Medicare will cover GLP-1 drugs prescribed solely for weight loss for eligible beneficiaries at a $50 monthly copay.